Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113775 - 113775
Опубликована: Апрель 1, 2025
Язык: Английский
Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113775 - 113775
Опубликована: Апрель 1, 2025
Язык: Английский
Advanced Healthcare Materials, Год журнала: 2025, Номер unknown
Опубликована: Март 4, 2025
Abstract Inflammation is essential for pathogen eradication and tissue repair; However, chronic inflammation can bring on multi‐organ dysfunction due to an overproduction of reactive oxygen species (ROS). Among various anti‐inflammatory agents, polyphenol‐based nanotherapeutics offer potential advantages, including enhanced stability, targeted delivery, multiple therapeutic functions, personalized therapy tailored the severity. Despite these development biocompatible nanomedicines capable selective accumulation in inflamed tissues efficient inhibition ROS‐induced inflammatory signaling pathways remains a considerable challenge. In this study, novel nanotherapeutic engineered through temperature‐dependent condensation polyphenolic catechin facilitated by hydrothermal reactions. The resulting catechin‐condensed (CCN150), synthesized at relatively low temperature, retains physicochemical functional properties akin its precursor, catechin, but with marked enhancement water solubility. CCN150 protects cells from oxidative stress eliminating intracellular ROS augmenting antioxidant enzymes. vivo studies reveal that intravenously administered predominantly accumulates tissues, minimal distribution healthy regions. Furthermore, effectively reduces systemic mouse models disrupting cycles instigated pro‐inflammatory milieu. Exhibiting negligible toxicity, holds substantial promise extensive applications treatment ROS‐mediated diseases.
Язык: Английский
Процитировано
0Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113775 - 113775
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0